Study setting {9}
This is a mono center study performed at the department of Otorhinolaryngology in the University Medical Center Utrecht, an academic hospital, and is expected to run for approximately three years.
Eligibility criteria {10}
All participants will undergo the usual standard medical care of work-up before, during and after during cochlear implantation. The work-up includes a pure tone audiogram (PTA), a speech audiogram, a preoperative CT, and interviews with speech therapist, audiologist, ENT surgeon and social worker. In a multidisciplinary meeting, the Cochlear implantation team of the UMC Utrecht will assess all results and decide whether a patient is eligible for a CI. In addition, according to standard medical care, participants will receive corticosteroids before and after surgery.
Inclusion Criteria
- Dutch language proficiency
- 18 years or older
- Choice for Advanced Bionics implant
- No signs of acute or chronic middle ear infections and/or mastoiditis
Exclusion Criteria
- Prior otologic surgery in the implanted ear (excluding tympanostomy tube placement)
- Inner ear malformation (i.e. ossification, Mondini malformation)
- Retrocochlear pathology
- Neurocognitive disorders
- Acute or Chronic otomastoiditis
Who will take informed consent? {26a}
Participants ENT-physician or audiologist during visits to the outpatient clinic will asks whether the patient would be interested to participate in the study. Additional verbal and written information about the study will be provided to all participants by an investigator. An investigator will also provide and obtain the informed consent (IC) form, which is also co-signed by the investigator. There will be ample opportunity (at least 1 week) for the participants to consider participation and discuss their questions with one of the investigators before the participants may decide to sign the IC form in order to participate. Participation in the study is entirely voluntary. If a subject wants to participate, several appointments for the audiological follow-up will be scheduled. If a patient does not want to participate, contact with the investigator will be terminated.
Additional consent provisions for collection and use of participant data and biological specimens {26b}
Not applicable, no additional consent is required for use of participant data and biological specimens.
Interventions
Explanation for the choice of comparators {6b}
Four groups of participants will be included, which all have a different combination of electrode type, and surgical insertion approach. These treatment options are all standard care in cochlear implants centers worldwide.
Intervention description {11a}
The electrode type consists of either a lateral wall electrode array, or a perimodiolar electrode array, specifically, respectively the SlimJ and Midscala electrode arrays. Both these arrays are developed by Advanced Bionics. Two surgical approaches are used, a round window or cochleostomy approach. The cochleostomy is placed antero-inferiorly from the round window niche.
Criteria for discontinuing or modifying allocated interventions {11b}
It is only possible to change the allocated intervention via a second surgery, by removing the cochlear implant. A second surgery increases potential harm for the patient, outweighing potential benefits. Therefore, removal of the cochlear implant is only performed if medically necessitated, e.g. in instances of malfunctioning device, wound infection or persisting pain. Such rare cases will be discussed in a plenary session dedicated for cochlear implant patients, in line with normal standard medical care.
Strategies to improve adherence to interventions {11c}
To improve adherence to the study protocol, the follow-up measurements for the study are planned simultaneously with the standard medical rehabilitation appointments. Apart from showing up for the follow-up appointments, participants do not need to adhere to specific tasks.
Relevant concomitant care permitted or prohibited during the trial {11d}
Not applicable, there is no relevant concomitant care that is permitted or prohibited.
Provisions for post-trial care {30}
The sponsor has an insurance which is in accordance with the legal requirements in the Netherlands (Article 7 WMO). This insurance provides cover for damage to research participants through injury or death caused by the study. The insurance applies to the damage that becomes apparent during the study or within 4 years after the end of the study.
Outcomes {12}
At intake baseline data will be collected, including gender, age, duration of deafness, pre- or post-lingually deafened, cause of deafness and side of implantation. In addition, the most recent pure tone thresholds (250 Hz, 500 Hz and 1, 2, 4, and 8 kHz) and speech reception thresholds (SRT) for consonant-vowel-consonant (CVC) word lists in quiet for both ears will be collected.
Hearing preservation
Hearing preservation is calculated by comparing pure-tone thresholds after and before CI surgery using the following equation (30), Eqn. 1:
In this equation, HP is hearing preservation, is the average pure-tone (unaided) hearing threshold of 125, 250 and 500 Hz measured preoperatively,PTApost is the same average pure-tone hearing threshold measured postoperatively, and PTAmax is the maximum sound intensity generated by a standard audiometer (usually between 90 and 120 dB HL). With full preservation of hearing, HP=100, and with complete loss of hearing HP=0. The postoperative tone audiometry will also be measured at 3, 6 and 12 months after activation of the cochlear implant.
Scalar positioning of the electrode array
We will use the CB-CT scanner (Newtom VGi EVO, Cefla Italy) to postoperatively assess the scalar location of the electrode array in cochlea’s of all four groups. The CB-CT has been proven to be the best imaging modality to date, for assessing the scalar location postoperatively, as it has low radiation artefacts (caused by the metal parts of the cochlear implant) and high spatial resolution needed to image the cochlea and its internal parts. Other advantages of this modality are amongst others that it has relatively low radiation exposure, is less likely to trigger claustrophobic events and requires shorter scanning durations compared to traditional CT scanners (31-33). CB-CT imaging postoperatively leads to exposure of low-dose radiation (effective dose: 0.18 mSv), and is therefore considered to be of low-risk.
We will assess CI translocation by making multiplanar midmodiolar reconstructions of the CB-CT images, which is validated (23-25). These multiplanar reconstructions will allow us to systematically indicate for every electrode contact of the electrode array the exact scalar position (i.e. scala tympani or scala vestibuli).
Electrocochleography
Electrocochleography (ECochG) is a method for recording the electrical potentials of the cochlea. The ECochG is composed of several components: the compound action potential (CAP), auditory nerve neurophonic (ANN), cochlear microphonics (CM) and the summating potential (SP). In essence, the CAP and ANN reflect auditory nerve activity, the CM and SP are generated by the hair cells of the organ of Corti. The CM is an alternating current response following the tone, and the SP is a direct current response. Outcome measures include the total ECochG amplitude. Potentially, the difference in the amplitude of the total ECochG response after and before insertion might contain information about insertion trauma, i.e. damage to the basilar membrane, stria vascularis or other structures.
Intraoperatively we will use the most apical contact point of the electrode array to measure these outcomes during insertion. The acoustic pure tones stimuli will be delivered via an earphone (earplug) on the operated ear. This will be coupled to the measurement equipment (active insertion monitoring system, Advanced Bionics) that is provided by the manufacturer. The amplifier in the implant will be used for amplification of the response. Apart from prolonged surgery time (estimate of 10 mins), there will be no added risk for the participant. Postoperatively ECochG measurements will be repeated. We will perform recordings at each of the 16 electrodes for the following frequencies: 125, 250, 500 Hz and 1, 2, 3, 4 kHz. In addition, acoustic tone thresholds will be indirectly estimated by measures of the total ECochG responses.
Speech perception
One year after activation of the CI, a conventional speech perception test in quiet and in noise will be performed with CVC words from the ‘Nederlandse Vereniging voor Audiologie’ (NVA: Dutch Society of Audiology) word-list. Speech reception thresholds will be registered. Also, the clinical spectral ripple test, which uses ripples instead of words, can be used to complement speech perception scores in noise (34).
The extra ECochG measurements and tone/speech tests are not considered to be of any risk for the participants.
Participant timeline {13}
Schedule of enrolment, interventions, and assessments is depicted in Figure 1. Participants will be screened and enrolled two weeks before the surgery. On the day of surgery the participant will be allocated to one of the four groups (A-D). During surgery intraoperative ECochG measure will be conducted. The CB-CT scan will be performed on the same day after surgery. Activation of the CI is approximately 4-6 weeks after surgery. After activation of the CI, the first audiometry and postoperative ECochG measures will be conducted. These measurements will be repeated at approximately 2, 5 and 12 months after activation of the CI.
Sample size {14}
Hearing preservation as computed according to Eqn. 1 is the main outcome variable. Based on three studies in literature (35-37) we expect a large range of hearing preservation for each group, from 0 (no preservation, i.e., loss of all hearing) to 100 (full preservation, hearing stable), and occasionally above (improved hearing). These three studies showed means of 56, 74, and 53, respectively and within-group standard deviations, σW, of 37, 19 and 37. Weighing the larger studies (35, 37) more we estimate σW = 35, group means of 50 with clinically interesting differences of 40 between best and worst group means. This yields a variance between groups of 400, i.e., σB = √400 = 20 (σB: standard deviation between groups). Thus, effect size σB/ σW = 0.57. Using a group size of 12 yields a robust power of 0.9. We used G*power (version 3.1.9) to calculate the power based on effect size and sample size with a one-way ANOVA test, with fixed effects.
Recruitment {15}
No particular strategies were developed to increase the likelihood of participant enrolment. However, in developing the protocol, efforts were made to limit the extra burden for participants participating in this study. For example, follow-up measurements are planned on the same days of rehabilitation appointments. Also, based on previous experience and data, we expect to achieve adequate participant enrolment to reach our targeted sample size.
Assignment of interventions: allocation
Sequence generation {16a}
A separate independent department, the Julius Research and Epidemiology Department of the University Medical Center Utrecht, will handle the method of generating the allocation sequence. They will stratify the groups for age, with two subgroups, 18-50 years and equal or more than 50 years. Beforehand, 8 numbers are created, indicating a combination of group (A-D) and stratification (below or equal to 50 and higher than 50 years).
Concealment mechanism {16b}
In a sequentially manner every participant will be allocated randomly a number from 4 numbers that are possible (based on age) by the research tool software of the Julius center and Epidemiology department. The allocation is tied to block randomization. The allocation will be done before surgery, and after IC approval and screening.
Implementation {16c}
The Julius centre and epidemiology department will generate the allocation sequence with their own developed research tool for randomisation. A participant can be included by every member of the research team, when in doubt, the inclusion will be judged by the whole research team. Subsequently, based on the allocation, the patient is assigned to one of the groups by a member of the research team.
Assignment of interventions: Blinding
Who will be blinded {17a}
This study is single-blind, meaning that only participants are blinded for the treatment allocation. Because of the nature of the intervention (type of surgery and intracochlearly placed electrode array), it is impossible for the patient to discover the allocation. The research team is not blinded. The audiology assistants, however, who will perform the audiometry, are blinded. In addition, the offline outcome data will be blindly analysed.
Procedure for unblinding if needed {17b}
In rare cases in which the device has to be removed via surgery unblinding may be permissible. Before the second surgery, the subject will be unblinded by a member of the research team, who will discuss the treatment options with the subject. If needed, the surgeon will also be informed about the exact intervention, as is standard in medical practice.
Data collection and management
Plans for assessment and collection of outcomes {18a}
All data will be collected using an electronic data capture (EDC) tool (Castor EDC). The UMC Utrecht healthcare data of the participants, including baseline outcomes, CT images and results of the audiometry will be derived from the electronic patient file. The assessors are specialized in otorhinolaryngology, and therefore they are trained in assessing the audiology, CT images and electrophysiology data of this study.
Plans to promote participant retention and complete follow-up {18b}
Once a participant is enrolled and randomized, the study site will make every reasonable effort to follow the subject for the entire study period. Participants can leave the study at any time for any reason if they wish to do so without any consequences. Participants who withdraw from the study or who terminate the recording sessions prematurely, in the absence of any adverse event, will not be followed. Participant retention will be increased by schedule strategies, e.g. by planning the follow-up measures on the same day of clinical rehabilitation. Participants will also be reminded of the study via e-mail between sessions, including information of any published results (if they are interested).
Data management {19}
All data will be handled confidentially and research data will be coded by using a unique patient identification number. To be able to reproduce the study finding and to help future users to understand and reuse the data all changes made to the raw data and all steps taken in the analysis will be documented. The database files will be kept for 15 years after the study has ended.
Confidentiality {27}
The key to the code will be safeguarded by the investigators. All data will be stored on the research network disc of the UMC Utrecht in a secured research folder structure. Only the team of investigators will have access to the database files.
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
Not applicable; no biological specimens will be collected for this study.
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
We will use an ANOVA test to compare the primary outcome measure hearing preservation between the four groups. We will do the same for the SRT thresholds (in quiet and in noise) between the groups. Fisher’s exact test of independence will be used to compare the electrode location within the scala tympani (correct location after insertion) between CO or RW approach, and between PM or LW electrode insertion. We will also use multiple regression analysis to identify independent predictors of hearing preservation. Among the factors to examine are insertion depth and cochlear volume. We will use a Pearson correlation test to examine the correlations between the ECochG responses and hearing preservation at the various time points (during and after cochlear implantation).
Interim analyses {21b}
Independent analysis of the Institutional Review Board (IRB) or in Dutch ‘Medisch Ethische Toetsing Commissie’ (METC) classified this study as a low risk, not needing a data safety monitoring committee (DSMC), mainly because all interventions are standard medical care. Therefore, no interim analyses will be conducted during this trial.
Methods for additional analyses (e.g. subgroup analyses) {20b}
No additional analyses will be conducted. Participants age might play an important role in outcomes, however the randomization procedures stratifies for age for every intervention group (A-D).
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}
Participants who withdraw from the study or who terminate the recording session prematurely will be considered as lost and will be replaced. Reasons for withdrawal or premature termination will be documented. We expect a withdrawal rate of participants of no more than 10% (since N=48, this is 5). The number of replacements will be limited to two persons per subgroup. Depending on the missing values, multiple imputation or simply list wise deletion will be conducted for the missing values.
Plans to give access to the full protocol, participant level-data and statistical code {31c}
Data sharing, including full protocol, participant datasets and statistical codes will be considered upon reasonable request.
Oversight and monitoring
Composition of the coordinating centre and trial steering committee {5d}
Trial quality will be independently monitored by a local monitor (UMC Utrecht) once a year. The local monitor will check at least 10% of the signed ICs. From the first five participants the in- and exclusion criteria will also be checked. The monocenter study file will be also monitored. This study has no public involvement group.
Composition of the data monitoring committee, its role and reporting structure {21a}
Not applicable, a data monitoring committee is not appointed for this study.
Adverse event reporting and harms {22}
Adverse events (AE) will be recorded; serious adverse events (SAE) will be reported to the local IRB, and centrally stored in a digital database. Serious adverse events are not expected, but in case they do occur, the research group can decide to terminate prematurely the study.
Frequency and plans for auditing trial conduct {23}
The investigators will submit a summary of the progress of the trial to the accredited IRB once a year. Information will be provided on the date of inclusion of the first subject, numbers of participants included and numbers of participants that have completed the trial, serious adverse events/serious adverse reactions, protocol violations, other problems, and amendments.
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}
Amendments are changes made to the research after a favourable opinion by the accredited IRB has been given. All protocol amendments will be notified to the IRB for approval. Non-substantial amendments will not be notified to the accredited IRB and the competent authority, but will be recorded and filed by the sponsor.
Dissemination plans {31a}
The trial results will be made accessible to the public in a peer-review journal, preferable in an open access-study journal. In addition, key trial results will be presented in national and international conferences and other relevant meetings. There are no publication restrictions.